Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Correction to: The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma.

Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P.

Cell Death Differ. 2019 Sep 5. doi: 10.1038/s41418-019-0405-7. [Epub ahead of print]

PMID:
31488891
2.

The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma.

Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P.

Cell Death Differ. 2019 Jul 8. doi: 10.1038/s41418-019-0386-6. [Epub ahead of print] Erratum in: Cell Death Differ. 2019 Sep 5;:.

PMID:
31285546
3.

Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.

Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C.

Mol Pharm. 2019 Aug 5;16(8):3361-3373. doi: 10.1021/acs.molpharmaceut.9b00018. Epub 2019 Jul 2.

PMID:
31265310
4.

ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.

Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C.

Int J Mol Sci. 2019 May 21;20(10). pii: E2505. doi: 10.3390/ijms20102505. Review.

5.

Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.

Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, Orecchia S, Ananthanarayanan P, Bironzo P, Grosso F, Tabbò F, Comunanza V, Alexa-Stratulat T, Bussolino F, Righi L, Novello S, Scagliotti GV, Riganti C.

Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32419. [Epub ahead of print]

PMID:
31107974
6.

Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?

Kopecka J, Gazzano E, Castella B, Salaroglio IC, Mungo E, Massaia M, Riganti C.

Semin Cell Dev Biol. 2019 May 18. pii: S1084-9521(18)30164-2. doi: 10.1016/j.semcdb.2019.05.008. [Epub ahead of print] Review.

PMID:
31100351
7.

Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.

Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbò F, Cartia CF, Passone E, Comunanza V, Ardissone F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C.

J Thorac Oncol. 2019 Aug;14(8):1458-1471. doi: 10.1016/j.jtho.2019.03.029. Epub 2019 May 9.

8.

Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution.

Muntoni E, Martina K, Marini E, Giorgis M, Lazzarato L, Salaroglio IC, Riganti C, Lanotte M, Battaglia L.

Pharmaceutics. 2019 Feb 2;11(2). pii: E65. doi: 10.3390/pharmaceutics11020065.

9.

Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells.

Riganti C, Contino M, Guglielmo S, Perrone MG, Salaroglio IC, Milosevic V, Giampietro R, Leonetti F, Rolando B, Lazzarato L, Colabufo NA, Fruttero R.

J Med Chem. 2019 Jan 24;62(2):974-986. doi: 10.1021/acs.jmedchem.8b01655. Epub 2019 Jan 9.

PMID:
30584838
10.

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.

Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J.

J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0.

11.

Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.

Mungo E, Bergandi L, Salaroglio IC, Doublier S.

Int J Mol Sci. 2018 Nov 10;19(11). pii: E3550. doi: 10.3390/ijms19113550.

12.

Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.

Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, Poulsen SA, Riganti C.

Mol Cancer Ther. 2018 Dec;17(12):2598-2609. doi: 10.1158/1535-7163.MCT-18-0533. Epub 2018 Sep 25.

PMID:
30254183
13.

New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro.

Salaroglio IC, Gazzano E, Kopecka J, Chegaev K, Costamagna C, Fruttero R, Guglielmo S, Riganti C.

Molecules. 2018 Jun 9;23(6). pii: E1401. doi: 10.3390/molecules23061401.

14.

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.

Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C.

Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26.

PMID:
29748013
15.

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R.

Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.

16.

Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.

Gazzano E, Rolando B, Chegaev K, Salaroglio IC, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C.

J Control Release. 2018 Jan 28;270:37-52. doi: 10.1016/j.jconrel.2017.11.042. Epub 2017 Dec 2.

PMID:
29191785
17.

PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy.

Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, Kopecka J, Riganti C.

Mol Cancer. 2017 May 12;16(1):91. doi: 10.1186/s12943-017-0657-0.

18.

Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.

Battaglia L, Muntoni E, Chirio D, Peira E, Annovazzi L, Schiffer D, Mellai M, Riganti C, Salaroglio IC, Lanotte M, Panciani P, Capucchio MT, Valazza A, Biasibetti E, Gallarate M.

Nanomedicine (Lond). 2017 Mar;12(6):639-656. doi: 10.2217/nnm-2016-0380. Epub 2017 Feb 10.

PMID:
28186465
19.

P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.

Kopecka J, Rankin GM, Salaroglio IC, Poulsen SA, Riganti C.

Oncotarget. 2016 Dec 27;7(52):85861-85875. doi: 10.18632/oncotarget.13040.

20.

Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.

Buondonno I, Gazzano E, Jean SR, Audrito V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I, Mungo E, Hattinger CM, Deaglio S, Kelley SO, Serra M, Riganti C.

Mol Cancer Ther. 2016 Nov;15(11):2640-2652. Epub 2016 Jul 27.

21.

Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.

Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, Riganti C.

Oncotarget. 2015 Jan 20;6(2):1128-42.

22.

The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells.

Pinzón-Daza ML, Salaroglio IC, Kopecka J, Garzòn R, Couraud PO, Ghigo D, Riganti C.

J Cereb Blood Flow Metab. 2014 Aug;34(8):1258-69. doi: 10.1038/jcbfm.2014.100. Epub 2014 Jun 4.

23.

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D.

Neuro Oncol. 2013 Nov;15(11):1502-17. doi: 10.1093/neuonc/not104. Epub 2013 Jul 28.

24.

Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.

Riganti C, Salaroglio IC, Pinzòn-Daza ML, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Couraud PO, Bosia A, Ghigo D, Schiffer D.

Cell Mol Life Sci. 2014 Feb;71(3):499-516. doi: 10.1007/s00018-013-1397-y. Epub 2013 Jun 15.

Supplemental Content

Loading ...
Support Center